Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.
about
Maintenance treatment with antipsychotic drugs for schizophreniaBromperidol decanoate (depot) for schizophreniaBromperidol decanoate (depot) for schizophreniaCritical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophreniaSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeMedication adherence in schizophreniaRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesThe treatment of hallucinations in schizophrenia spectrum disordersComparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyEfficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysisUpdate on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsCurrent and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Integrating Emotions Into the Critical Interpretive Synthesis.Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewApproaches to improve adherence to pharmacotherapy in patients with schizophreniaDrug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Productivity and deadweight losses due to relapses of schizophrenia in JapanEffectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialDisparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsAntipsychotics, mood stabilisers, and risk of violent crimeLong-acting injectable antipsychotics for the maintenance treatment of bipolar disorder.Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication.Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaModeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in JapanRelapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsPaliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsThe Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.
P2860
Q24197902-2DFE9A3E-3813-414F-AD52-3A2C133EBAF6Q24202780-28D979C8-CFA7-45C2-A496-79FBB35EDE2CQ24234287-8A6C66C5-C661-4BD0-9D38-CF1D012820ABQ26745792-6EB46D9E-CF7C-490A-B378-D2CF164EDB1DQ26752965-74E2AEE4-24D7-44A6-8DDD-D50E3236DAECQ26823655-25BC11F0-EE8B-4750-B193-BFD16D02F5D5Q26863435-3DA6B314-2FA0-4EDB-914B-271D24BC29C8Q27025380-32309F1D-98CA-4436-B8D4-28ACE0AFF549Q27320151-AB70E9AB-2DE5-4E9D-823A-F4AB403C8DBAQ28078078-B94F324B-273F-4F48-B8F0-00628180D3C3Q28084069-B6F01AD7-9B8C-4079-B7DC-FCEAC166DC4DQ28085407-CC50D7D8-3C16-4E33-8925-831561832B8BQ30382281-BFA1EFDD-4749-4B64-8765-38A6C0165B12Q30386617-42B9EA19-C693-43F8-AA33-9406FE74DF3DQ30453929-DE6C2615-2CFB-48AD-98B8-C2070EFA4BF3Q30937746-2E32A42A-2B4E-4B98-9560-4AA32F484D05Q33589087-08DAFFA0-77B4-4848-A33A-C68407857FCEQ33645198-70C9EC68-E021-4A9D-989E-167E4F8D31ECQ33650097-3D76BE90-7751-4861-BA3A-08F75E3B9944Q33713733-2BA56996-C55B-4E23-B6AB-DD3F27BDDD8DQ33914295-DDB99E02-584C-4A6E-B689-49ACD54D23B6Q33953271-BDC2C109-E242-4D8B-91F1-47701FD8D9EEQ34048194-8DB4B7D9-4587-4D07-BABC-42F8DEF28B49Q34194840-8B9E622F-06D9-43DA-9A0B-75A34011F7AAQ34267385-F80E9629-8F7E-4901-B85F-13DB931E36B9Q34293855-00E04FFE-1C0A-4C0B-9584-2518F8BB1D59Q34293899-E8531824-CEC0-4038-8054-028B723A73BEQ34315836-8EF4777F-C848-463D-9811-604294EA9881Q34357174-1C442440-CC27-449C-9CB3-60C0E570E6B0Q34418847-FF5F1975-585C-4CC1-B30E-C6DB6BEDEF4CQ34548527-06EA59E1-E45B-40A1-909E-FBAE9946FA60Q34642820-CE7C133B-D334-4B8C-BDDD-722439E967ACQ34990923-EE31C924-4C6F-426E-B0C5-C32A3D7B5500Q35073474-5DEDDFF1-05CA-4696-98DE-D379FFF95304Q35186007-A56D5036-9A47-4BAF-A54D-726E9C8B88DBQ35659829-F6352825-7E57-4C67-9E28-95A663697B21Q35873789-91F74457-01A1-4AB3-A92E-C5AE68B877C4Q35882300-326B04CC-C34B-4DF4-BC11-2F8179DD27B7Q36001512-CC0EF64E-942B-4F20-8ED3-B8806D627A20Q36059843-C4139827-E2D8-4531-8B7D-825A1678C26B
P2860
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Oral versus depot antipsychoti ...... f randomised long-term trials.
@ast
Oral versus depot antipsychoti ...... f randomised long-term trials.
@en
Oral versus depot antipsychoti ...... f randomised long-term trials.
@nl
type
label
Oral versus depot antipsychoti ...... f randomised long-term trials.
@ast
Oral versus depot antipsychoti ...... f randomised long-term trials.
@en
Oral versus depot antipsychoti ...... f randomised long-term trials.
@nl
prefLabel
Oral versus depot antipsychoti ...... f randomised long-term trials.
@ast
Oral versus depot antipsychoti ...... f randomised long-term trials.
@en
Oral versus depot antipsychoti ...... f randomised long-term trials.
@nl
P2093
P1476
Oral versus depot antipsychoti ...... f randomised long-term trials.
@en
P2093
Claudia Leucht
John M Davis
John M Kane
Stefan Leucht
Stephan Heres
Werner Kissling
P356
10.1016/J.SCHRES.2010.11.020
P407
P577
2011-01-22T00:00:00Z